Loading...
Oral contraceptives (OCs) have long been known to protect against ovarian cancer. These researchers sought to determine whether OCs containing progestins with higher androgenic properties are less protective than other OCs. Included in their analysis were 568 women (age range, 20–69) with ovarian cancer who were selected from a study of contraception and cancer risk factors, and 1026 age- and race-matched women without ovarian cancer who were selected by random telephone calling or from lists supplied by the Health Care Financing Administration.
Participants completed standardized, 1.5-hour, in-person interviews on demographics, medical history, and past OC use, which was classified as androgenic, nonandrogenic, both types, or none. Women wi…